Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: yamasaki r. Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220. Blood. 2022. PMID: 35580269 Free PMC article.
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.
Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Mashima K, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Sugimoto M, Ishihara Y, Ashizawa M, Hatano K, Sato K, Oh I, Fujiwara SI, Ueda M, Ohmine K, Muroi K, Kanda Y. Yamamoto C, et al. Among authors: yamasaki r. Blood Adv. 2019 Nov 12;3(21):3266-3277. doi: 10.1182/bloodadvances.2019000745. Blood Adv. 2019. PMID: 31698458 Free PMC article.
Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis.
Minakata D, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Minakata D, et al. Among authors: yamasaki r. Leuk Res. 2022 Jan;112:106750. doi: 10.1016/j.leukres.2021.106750. Epub 2021 Nov 11. Leuk Res. 2022. PMID: 34798568
The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
Nakano H, Fujiwara SI, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Nakano H, et al. Among authors: yamasaki r. Hematol Oncol. 2017 Sep;35(3):357-364. doi: 10.1002/hon.2277. Epub 2015 Dec 7. Hematol Oncol. 2017. PMID: 26639319
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Minakata D, et al. Among authors: yamasaki r. Leuk Res. 2016 Mar;42:82-7. doi: 10.1016/j.leukres.2015.12.013. Epub 2016 Jan 2. Leuk Res. 2016. PMID: 26790727
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara S, Ohmine K, Suzuki T, Muroi K, Kanda Y. Yamamoto C, et al. Among authors: yamasaki r. Leuk Lymphoma. 2016 Nov;57(11):2541-7. doi: 10.3109/10428194.2016.1153087. Epub 2016 Feb 25. Leuk Lymphoma. 2016. PMID: 26917050
Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Umino K, et al. Among authors: yamasaki r. Leuk Lymphoma. 2017 Feb;58(2):316-323. doi: 10.1080/10428194.2016.1190975. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27267694
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara S, Okazuka K, Hatano K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y. Sugimoto M, et al. Among authors: yamasaki r. Ann Hematol. 2016 Sep;95(9):1513-9. doi: 10.1007/s00277-016-2740-9. Epub 2016 Jul 1. Ann Hematol. 2016. PMID: 27365141
High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement.
Umino K, Fujiwara SI, Sato K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Umino K, et al. Among authors: yamasaki r. Acta Haematol. 2017;137(2):93-99. doi: 10.1159/000454890. Epub 2017 Jan 25. Acta Haematol. 2017. PMID: 28118621
Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Umino K, et al. Among authors: yamasaki r. Hematology. 2017 Oct;22(9):521-526. doi: 10.1080/10245332.2017.1312204. Epub 2017 Apr 17. Hematology. 2017. PMID: 28413914
507 results